文献速递临床试验与 GCP基础与转化研究

伊布司特治疗酒精使用障碍:II期随机临床试验方案

Ibudilast for alcohol use disorder: study protocol for a phase II randomized clinical trial.
PubMed 文献 · Trials · 2020-09-11

本研究为12周双盲安慰剂对照随机临床试验,计划随机132名当前酒精使用障碍患者,接受伊布司特50 mg每日两次治疗。主要结局为重度饮酒天数百分比,次要结局包括每日饮酒量、戒酒天数百分比等饮酒指标及渴求与负性情绪,并探索神经影像和炎症标志物。

要点

  • 伊布司特50 mg每日两次治疗酒精使用障碍的II期随机对照试验
  • 主要结局为重度饮酒天数百分比,计划样本量132例
  • 探索伊布司特对压力、神经炎症和酒精线索反应性的生物机制

核心结论

  • 该研究旨在进一步开发伊布司特作为酒精使用障碍的新型治疗药物,并探索其作用机制。
  • 若伊布司特优于安慰剂,将为后续多中心确证性试验及FDA批准奠定基础。

研究设计与样本

  • 12周双盲安慰剂对照随机临床试验,计划随机132名寻求治疗的当前酒精使用障碍男性和女性。
  • 伊布司特剂量为50 mg每日两次。

关键数值与推荐

  • 主要结局为重度饮酒天数百分比(PHDD)。
  • 次要饮酒结局包括每日饮酒量、每次饮酒日饮酒量、戒酒天数百分比、无重度饮酒天数受试者百分比和戒酒受试者百分比,以及酒精渴求和负性情绪测量。
  • 参与者可选择参加神经影像学检查,评估伊布司特对社会心理压力和酒精线索的神经激活效应。
  • 收集血浆促炎标志物水平以及主观和生物学(唾液皮质醇)压力反应标志物。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Alcohol use disorder (AUD) is a chronic and relapsing condition for which current pharmacological treatments are only modestly effective. The development of efficacious medications for AUD remains a high research priority with recent emphasis on identifying novel molecular targets for AUD treatment and to efficiently screen new compounds aimed at those targets. Ibudilast, a phosphodiesterase inhibitor, has been advanced as a novel addiction pharmacotherapy that targets neurotrophin signaling and neuroimmune function. METHODS: This study will conduct a 12-week, double-blind, placebo controlled randomized clinical trial of ibudilast (50 mg BID) for AUD treatment. We will randomize 132 treatment-seeking men and women with current AUD. We will collect a number of alcohol consumption outcomes. Primary among these is percent heavy drinking days (PHDD); secondary drinking outcomes include drinks per day, drinks per drinking day, percent days abstinent, percent subjects with no heavy drinking days, and percent subjects abstinent, as well as measures of alcohol craving and negative mood. Additionally, participants will have the option to opt-in to a neuroimaging session in which we examine the effects of ibudilast on neural activation to psychosocial stress and alcohol cues. Finally, we will also collect plasma levels of proinflammatory markers, as well as subjective and biological (salivary cortisol) markers of stress response. DISCUSSION: This study will further develop ibudilast, a safe and promising novel compound with strong preclinical and clinical safety data for AUD, and will probe biological mechanisms underlying the effects of Ibudilast on stress, neuroinflammation, and alcohol cue-reactivity and craving. If ibudilast proves superior to placebo in this study, it will set the stage for a confirmatory multi-site trial leading to FDA approval of a novel AUD treatment. TRIAL REGISTRATION: ClinicalTrials.gov NCT03594435 "Ibudilast for the Treatment of Alcohol Use Disorder". Registered on 20 July 2018.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Burnette EM, Baskerville WA, Grodin EN, et al. Ibudilast for alcohol use disorder: study protocol for a phase II randomized clinical trial. Trials. 2020. PMID: 32912290. doi:10.1186/s13063-020-04670-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。